Search Results - "Advani, Sunil"

Phase I Trial of Intravenous Oncolytic Vaccinia Virus (GL-ONC1) with Cisplatin and Radiotherapy in Patients with Locoregionally Advanced Head and Neck Carcinoma by Mell, Loren K, Brumund, Kevin T, Daniels, Gregory A, Advani, Sunil J, Zakeri, Kaveh, Wright, Mary E, Onyeama, Sara-Jane, Weisman, Robert A, Sanghvi, Parag R, Martin, Peter J, Szalay, Aladar A

“…Preclinical models have shown that the effectiveness of GL-ONC1, a modified oncolytic vaccinia virus, is enhanced by radiation and chemotherapy. The purpose of…”
Get full text

Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy by Hingorani, Dina V., Allevato, Michael M., Camargo, Maria F., Lesperance, Jacqueline, Quraishi, Maryam A., Aguilera, Joseph, Franiak-Pietryga, Ida, Scanderbeg, Daniel J., Wang, Zhiyong, Molinolo, Alfredo A., Alvarado, Diego, Sharabi, Andrew B., Bui, Jack D., Cohen, Ezra E. W., Adams, Stephen R., Gutkind, J. Silvio, Advani, Sunil J.

“…Locally advanced cancers remain therapeutically challenging to eradicate. The most successful treatments continue to combine decades old non-targeted…”
Get full text

A FZD7-specific Antibody-Drug Conjugate Induces Ovarian Tumor Regression in Preclinical Models by Do, Myan, Wu, Christina C N, Sonavane, Pooja R, Juarez, Edwin F, Adams, Stephen R, Ross, Jason, Rodriguez Y Baena, Alessandra, Patel, Charmi, Mesirov, Jill P, Carson, Dennis A, Advani, Sunil J, Willert, Karl

“…Although WNT signaling is frequently dysregulated in solid tumors, drugging this pathway has been challenging due to off-tumor effects. Current clinical…”
Get full text

MicroRNA regulation of endothelial TREX1 reprograms the tumour microenvironment by Wilson, RaeAnna, Espinosa-Diez, Cristina, Kanner, Nathan, Chatterjee, Namita, Ruhl, Rebecca, Hipfinger, Christina, Advani, Sunil J., Li, Jie, Khan, Omar F., Franovic, Aleksandra, Weis, Sara M., Kumar, Sushil, Coussens, Lisa M., Anderson, Daniel G., Chen, Clark C., Cheresh, David A., Anand, Sudarshan

“…Rather than targeting tumour cells directly, elements of the tumour microenvironment can be modulated to sensitize tumours to the effects of therapy. Here we…”
Get full text

Establishment of Patient-Derived Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response by Yebra, Mayra, Bhargava, Shruti, Kumar, Avi, Burgoyne, Adam M, Tang, Chih-Min, Yoon, Hyunho, Banerjee, Sudeep, Aguilera, Joseph, Cordes, Thekla, Sheth, Vipul, Noh, Sangkyu, Ustoy, Rowan, Li, Sam, Advani, Sunil J, Corless, Christopher L, Heinrich, Michael C, Kurzrock, Razelle, Lippman, Scott M, Fanta, Paul T, Harismendy, Olivier, Metallo, Christian, Sicklick, Jason K

“…Gastrointestinal stromal tumor (GIST) is the most common sarcoma of the gastrointestinal tract, with mutant succinate dehydrogenase ( ) subunits (A-D)…”
Get full text

Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize by Adams, Stephen R., Yang, Howard C., Savariar, Elamprakash N., Aguilera, Joe, Crisp, Jessica L., Jones, Karra A., Whitney, Michael A., Lippman, Scott M., Cohen, Ezra E. W., Tsien, Roger Y., Advani, Sunil J.

“…Tumour resistance to radiotherapy remains a barrier to improving cancer patient outcomes. To overcome radioresistance, certain drugs have been found to…”
Get full text

Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability by Hingorani, Dina V, Doan, Matthew K, Camargo, Maria F, Aguilera, Joseph, Song, Seung M, Pizzo, Donald, Scanderbeg, Daniel J, Cohen, Ezra E W, Lowy, Andrew M, Adams, Stephen R, Advani, Sunil J

“…The most successful therapeutic strategies for locally advanced cancers continue to combine decades-old classical radiosensitizing chemotherapies with…”
Get full text

Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery by Buckel, Lisa, Savariar, Elamprakash N, Crisp, Jessica L, Jones, Karra A, Hicks, Angel M, Scanderbeg, Daniel J, Nguyen, Quyen T, Sicklick, Jason K, Lowy, Andrew M, Tsien, Roger Y, Advani, Sunil J

“…Intrinsic tumor resistance to radiotherapy limits the efficacy of ionizing radiation (IR). Sensitizing cancer cells specifically to IR would improve tumor…”
Get full text

Kinase-independent role for CRAF-driving tumour radioresistance via CHK2 by Advani, Sunil J., Camargo, Maria Fernanda, Seguin, Laetitia, Mielgo, Ainhoa, Anand, Sudarshan, Hicks, Angel M., Aguilera, Joseph, Franovic, Aleksandra, Weis, Sara M., Cheresh, David A.

“…Although oncology therapy regimens commonly include radiation and genotoxic drugs, tumour cells typically develop resistance to these interventions. Here we…”
Get full text

Redirecting extracellular proteases to molecularly guide radiosensitizing drugs to tumors by Hingorani, Dina V., Crisp, Jessica L., Doan, Matthew K., Camargo, Maria F., Quraishi, Maryam A., Aguilera, Joseph, Gilardi, Mara, Gross, Larry A., Jiang, Tao, Li, Wei T., Ongkeko, Weg M., Cohen, Ezra E.W., Gutkind, J. Silvio, Adams, Stephen R., Advani, Sunil J.

“…Patients with advanced cancers are treated with combined radiotherapy and chemotherapy, however curability is poor and treatment side effects severe. Drugs…”
Get full text

Radiation-Drug Combinations to Improve Clinical Outcomes and Reduce Normal Tissue Toxicities: Current Challenges and New Approaches: Report of the Symposium Held at the 63rd Annual Meeting of the Radiation Research Society, 15–18 October 2017; Cancun, Mexico by Falls, Kelly C., Sharma, Ricky A., Lawrence, Yaacov R., Amos, Richard A., Advani, Sunil J., Ahmed, Mansoor M., Vikram, Bhadrasain, Coleman, C. Norman, Prasanna, Pataje G.

“…The National Cancer Institute's (NCI) Radiation Research Program (RRP) is endeavoring to increase the relevance of preclinical research to improve outcomes of…”
Get full text

Tumor Activated Cell Penetrating Peptides to Selectively Deliver Immune Modulatory Drugs by Hingorani, Dina V, Camargo, Maria F, Quraishi, Maryam A, Adams, Stephen R, Advani, Sunil J

“…Recent advances in immunotherapy have revolutionized cancer therapy. Immunotherapies can engage the adaptive and innate arms of the immune system. Therapeutics…”
Get full text

A MEK-independent role for CRAF in mitosis and tumor progression by Mielgo, Ainhoa, Seguin, Laetitia, Huang, Miller, Camargo, Maria Fernanda, Anand, Sudarshan, Franovic, Aleksandra, Weis, Sara M, Advani, Sunil J, Murphy, Eric A, Cheresh, David A

“…Raf kinase activity is deregulated in cancers and is thought to promote tumor growth by inducing proliferation signaling through MEK/Erk. This report…”
Get full text

A novel 3D‐printed phantom insert for 4D PET/CT imaging and simultaneous integrated boost radiotherapy by Cerviño, Laura, Soultan, Dima, Cornell, Mariel, Yock, Adam, Pettersson, Niclas, Song, William Y., Aguilera, Joseph, Advani, Sunil, Murphy, James, Hoh, Carl, James, Claude, Paravati, Anthony, Coope, Robin, Gill, Bradford, Moiseenko, Vitali

“…Purpose To construct a 3D‐printed phantom insert designed to mimic the variable PET tracer uptake seen in lung tumor volumes and a matching dosimetric insert…”
Get full text

An in vitro study for the dosimetric and radiobiological validation of respiratory gating in conventional and hypofractionated radiotherapy of the lung: effect of dose, dose rate, and breathing pattern by Cerviño, Laura I, Soultan, Dima, Advani, Sunil J, Cornell, Mariel, Yock, Adam, Pettersson, Niclas, Song, William Y, Aguilera, Joseph, Murphy, James, Hoh, Carl, James, Claude, Paravati, Anthony, Coope, Robin, Gill, Bradford, Moiseenko, Vitali

“…Stereotactic body radiotherapy (SBRT) of the lung has become a standard of care for early-stage inoperable non-small cell lung cancer (NSCLC). A common…”
Get more information

Combination of fractionated irradiation with anti‐VEGF expressing vaccinia virus therapy enhances tumor control by simultaneous radiosensitization of tumor associated endothelium by Buckel, Lisa, Advani, Sunil J., Frentzen, Alexa, Zhang, Qian, Yu, Yong A., Chen, Nanhai G., Ehrig, Klaas, Stritzker, Jochen, Mundt, Arno J., Szalay, Aladar A.

“…Oncolytic viruses are currently in clinical trials for a variety of tumors, including high grade gliomas. A characteristic feature of high grade gliomas is…”
Get full text

Preferential Replication of Systemically Delivered Oncolytic Vaccinia Virus in Focally Irradiated Glioma Xenografts by ADVANI, Sunil J, BUCKEL, Lisa, CHEN, Nanhai G, SCANDERBEG, Daniel J, GEISSINGER, Ulrike, QIAN ZHANG, YU, Yong A, AGUILAR, Richard J, MUNDT, Arno J, SZALAY, Aladar A

“…Radiotherapy is part of the standard of care in high-grade gliomas but its outcomes remain poor. Integrating oncolytic viruses with standard anticancer…”
Get full text

Abstract 977: RNA-sequencing analysis implicates novel non-coding RNAs in human papillomavirus-associated head and neck squamous cell carcinoma by Zou, Angela E., Krishnan, Aswini R., Xuan, Yinan, Saad, Maarouf A., Korrapati, Avinaash, Advani, Sunil J., Wang-Rodriguez, Jessica, Ongkeko, Weg

“…Abstract Head and neck squamous cell carcinoma (HNSCC) is an aggressive disease marked by frequent recurrence and metastasis and stagnant survival rates. Given…”
Get full text

Clinical and cosmetic outcomes in patients treated with high-dose-rate electronic brachytherapy for nonmelanoma skin cancer by Paravati, Anthony J., Hawkins, Peter G., Martin, Amanda N., Mansy, Gina, Rahn, Doug A., Advani, Sunil J., Hoisak, Jeremy, Dragojevic, Irena, Martin, Peter J., Miller, Charles J., Sanghvi, Parag

“…To retrospectively analyze clinical and cosmetic outcomes in patients treated for nonmelanoma skin cancer (NMSC) with high-dose-rate (HDR) electronic…”
Get full text

Combined TP53 mutation/3p loss correlates with decreased radiosensitivity and increased matrix-metalloproteinase activity in head and neck carcinoma by Raju, Sharat C, Hauff, Samantha J, Lemieux, Aaron J, Orosco, Ryan K, Gross, Andrew M, Nguyen, Linda T, Savariar, Elamprakash, Moss, William, Whitney, Michael, Cohen, Ezra E, Lippman, Scott M, Tsien, Roger Y, Ideker, Trey, Advani, Sunil J, Nguyen, Quyen T

“…Summary Objective Patients with head and neck squamous cell carcinoma (HNSCC) containing TP53 mutation and 3p deletion (“double-hit”) have poorer prognosis…”
Get full text